generations of glp 1 agonists Science Behind GIP and Glucagon Receptor for Obesity Research | News & Announcements Mechanisms of GLP-1 Receptor Agonist-Induced
Description
An increased risk of diabetic retinopathy has been reported in a clinical trial of semaglutide, which has been hypothesised to be related to the magnitude and rapidity of glucose lowering [61]

3.Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR

While this study was not a head-to-head clinical trial comparison, it may be relevant that at week 12 of a weekly dosing regimen, some studies suggest that participants treated with semaglutide (Wegovy, Novo Nordisk) had an approximately 6% decrease from baseline in body weight, whereas those treated with tirzepatide (Zepbound, Eli Lilly) had an approximately 8% decrease from baseline in body weight at the same time period, Bays said
Clinical studies continue to increase, yet the dermatological effects of these treatments remain poorly understood and lack adequate characterization

The rate of new onset of heart failure (HR 0.92

Unique 14-In-1 For GLP-1 UP: A natural GLP1 formula built around wild bitter melon, berberine, Akkermansia muciniphila, and cinnamon designed to work with the body's innate GLP1 secretion pathways
